Inclusion Criteria:

          -  Patients diagnosed with AML meeting one of the following criteria:

               -  Newly diagnosed, age 60 and older

               -  High risk cytogenetics and molecular abnormalities (National Comprehensive Cancer
                  Network [NCCN] criteria)

               -  Relapsed or refractory to prior chemotherapy

               -  Secondary AML

          -  Any prior chemotherapy must have been completed >= 2 weeks prior to day 1 of study
             treatment and the participant must have recovered to eligibility levels from prior
             toxicity

               -  Only one prior regimen is allowed for relapsed AML patients; note one prior
                  regimen is defined as follows:

                    -  Induction chemotherapy followed by consolidation is considered one regimen

                    -  Induction chemotherapy followed by re-induction in case of persistent
                       disease followed by consolidation is considered one regimen

               -  Hydroxyurea is allowed prior to day 1 of study treatment to keep white blood cell
                  (WBC) below 20 K

          -  Karnofsky performance status >= 60%

          -  Total bilirubin < 1.5 x institutional upper limit of normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 x institutional upper limit of normal

          -  Creatinine < 1.5 x institutional upper limit or normal OR creatinine clearance >= 60
             mL/min for patients with creatinine levels above 1.5 x institutional upper limit of
             normal

          -  Ejection fraction (EF) >= 45%

          -  Ability to understand and sign a written informed consent document

          -  Patients should not be receiving any other investigational agents

        Exclusion Criteria:

          -  Patients with clinically significant illness which would compromise participation in
             the study, including, but not limited to: active or uncontrolled infection, immune
             deficiencies or confirmed diagnosis of human immunodeficiency virus (HIV) infection,
             active hepatitis B, active hepatitis C, or uncontrolled diabetes, uncontrolled
             hypertension, symptomatic congestive heart failure, unstable angina pectoris,
             myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmias; or
             psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Patients with additional (other than AML) currently active primary malignancy other
             than curatively treated carcinoma in situ (CIS) of the cervix, or basal or squamous
             cell carcinoma of the skin; patients are not considered to have a "currently active"
             malignancy if they have completed therapy for a prior malignancy and disease free from
             prior malignancies for > 2 years

          -  Patients with active central nervous system (CNS) disease

          -  Patients with Chronic Myelogenous Leukemia (CML) in Myeloid blasts crisis

          -  Active infections, including opportunistic infections

          -  Women of childbearing potential (WOCBP) who have a positive serum pregnancy test
             within 14 days of the first administration of oral dasatinib